BERLIN / LONDON (IT BOLTWISE) – Bayer has received approval for its menopause drug Lynkuet in the EU. The drug, used to treat hot flashes, could become a major revenue driver for Bayer as the company struggles with expiring patents on other products.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Bayer has taken a significant step in the European pharmaceutical industry by receiving approval in the EU for its menopause drug Lynkuet. This medicine, which contains the active ingredient elinzanetant, is specifically approved for the treatment of moderate to severe hot flashes that are often associated with menopause or caused by hormone therapy for breast cancer.
With the EU approval, Bayer expands the availability of Lynkuet, which is already available in the USA, Australia, Canada, Great Britain and Switzerland. This expansion could be crucial for Bayer as it relies on the success of new drugs to offset lost sales from expiring patents, particularly for the anticoagulant Xarelto.
The launch of Lynkuet in the EU could help Bayer strengthen its position in the pharmaceutical market. The company hopes that Lynkuet will become a so-called blockbuster, a drug that generates more than $1 billion in sales annually. However, it is often a lengthy process for a drug to reach this sales mark.
Lynkuet’s approval in the EU comes at a time when the market for menopause drugs is growing. Experts see the increasing aging of the population and the increasing demand for specialized healthcare as a key driver for this market. With Lynkuet, Bayer could benefit from these trends and expand its market share in this segment.
In the pharmaceutical industry, developing new drugs is a complex and expensive process. The approval in the EU is an important milestone that underlines Bayer’s commitment to research and development. At the same time, it demonstrates the company’s ability to provide innovative solutions to health challenges.
The future of Lynkuet now depends on market acceptance and Bayer’s ability to market the drug effectively. However, with EU approval, Bayer has created a solid foundation to gain a foothold in this important market segment and consolidate its position as a leading pharmaceutical company.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Bayer brings new menopause drug Lynkuet to the EU”.